FAP and pulmonary fibrosis: The treatment with the FAP-targeted PI3K inhibitor slows lung fibrosis, suppresses the production of hydroxyproline (major building block of collagen), reduces collagen deposition, and extends life in mouse models of pulmonary fibrosis [45].